

**JUBILANT PHARMA LIMITED**  
(Company Registration No. 200506887H)  
(Incorporated in the Republic of Singapore)  
Registered office: 80 Robinson Road, #02-00, Singapore 068898

November 4, 2020

**Singapore Exchange Securities Trading Limited**  
11 North Buona Vista Drive #06-07  
The Metropolis Tower 2  
Singapore 138589

Dear Sirs,

We wish to intimate that Jubilant Pharma Limited ('Jubilant') has entered into a strategic partnership with SOFIE Biosciences, Inc. ('SOFIE'), USA. Under the terms of the partnership, Jubilant with 25% of equity holding shall be a strategic partner to SOFIE, enabling SOFIE to continue to grow production capacity, advance its theranostic pipeline, and support novel PET diagnostic manufacturing and distribution within the US.

Relevant details are given in **Annexure-A** to this letter.

We request you to take the same on record.

Thanking you,

Yours Faithfully,  
For Jubilant Pharma Limited

Sd/-  
Shyam S. Bhartia  
Chairman and Managing Director

Encl.: As above

**Details of Acquisition**

<b>Sr. No.</b>	<b>Particulars</b>	<b>Details</b>
1.	Name of the target entity, details in brief such as size, turnover etc.	SOFIE Biosciences, Inc., USA
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arms length”	Not Applicable
3.	Industry to which the entity being acquired belongs	Radiopharmaceuticals (a subset of the pharma industry)
4.	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	Strategic partnership between Jubilant and SOFIE will enable them to collaborate in the development, manufacturing and distributions of radiopharmaceuticals that will help in diagnosis and treatment of a wide variety of oncology diseases.
5.	Brief details of any governmental or regulatory approvals required for the acquisition	Not applicable.
6.	Indicative time period for completion of the acquisition	January 2021
7.	Nature of consideration - whether cash consideration or share swap and details of the same	Cash
8.	Cost of acquisition or the price at which the shares are acquired	US \$25,000,000
9.	Percentage of shareholding/ control acquired and/ or number of shares acquired;	25% of issued shares

<b>Sr. No.</b>	<b>Particulars</b>	<b>Details</b>
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	Relevant details are given below

## **SOFIE BIOSCIENCES INC. Executive Summary**

SOFIE's vision is to improve patient outcomes by developing and delivering molecular diagnostics and therapeutics (Theranostics). With its robust radiopharmaceutical production and distribution network, mature contract manufacturing services, and now, high value Theranostic intellectual property, SOFIE is poised to deliver on the promise of nuclear medicine.

- Date of incorporation: May 28, 2008
- Countries in Operation: USA
- In September 2017, SOFIE purchased Zevacor Pharma, a 15 site network for the manufacturing, contract manufacturing, and development of proprietary therapeutic and diagnostic radiopharmaceuticals.

- History of turnover:

2017	\$21,988,270 <sup>[1]</sup>
2018	\$64,298,520
2019	\$67,665,781

[1] Includes Zevacor's revenue for the last 4 months of the year.

- Current Business:
  - Commercial manufacturing and distribution of radiopharmaceuticals, including 430,000+ annual FDG doses
  - Manufacturing and distribution of radiotherapeutics for Pharma partners
  - Intellectual Property: SOFIE licensed a family of theranostic compounds that target fibroblast activation protein, which is an established cancer target and has the potential to treat multiple tumors.